Cannabis Law and Access in Thailand

Thailand's cannabis framework: a case study in rapid legal change

Forty-seven countries now have some form of legal cannabis framework. Thailand's version is one of the most watched , and most misunderstood , of the lot. I've spent a fair bit of time over the past year reading through Thai ministerial notifications and Food and Drug Administration (FDA) circulars, partly because the policy architecture is genuinely unusual, and partly because Australian readers travelling to or following Thailand's experience keep asking the same question: what does the law actually say?

The short version is: it's complicated, it's still moving, and "decriminalised" is only a partial description of what happened.

From Schedule 5 narcotic to delisted plant

Cannabis was a Schedule 5 narcotic under Thailand's Narcotics Act B.E. 2522 (1979) for decades. Possession carried serious criminal penalties. That changed on 9 June 2022, when the Thai FDA delisted the cannabis plant , flowers, leaves, stem, root and seed; from Schedule 5. It was the first country in Asia to take a step like this at the national level.

But here is where people get into trouble. Delisting from the Narcotics Act did not mean open recreational legalisation. It meant the plant itself was no longer automatically a prohibited narcotic. Extracts with THC above 0.2% by weight remained a Schedule 5 controlled substance. And no comprehensive cannabis act filled the gap, the government expected the Cannabis and Hemp Act to pass quickly to regulate the sector, but as of mid-2025 that legislation remains stalled in Thailand's parliament.

What emerged instead was a patchwork: a delisted plant, existing food and cosmetic laws applied awkwardly to cannabis products, and a series of FDA notifications trying to manage what the core legislation had not yet resolved.

The 0.2% THC line and what it controls

The 0.2% threshold is doing a lot of work in Thai law. Products, oils, beverages, food items; containing cannabidiol (CBD) or other cannabinoids extracted from cannabis are only legal if the THC concentration stays below that threshold. Anything above 0.2% THC in an extract remains Schedule 5. That means high-potency extracts, concentrated resins, and products intended to produce intoxication are still controlled substances under the Narcotics Act, regardless of the 2022 delisting of the plant itself.

THC is the primary psychoactive cannabinoid in cannabis, binding to CB1 receptors in the central nervous system. Its scheduling in Thailand's remaining framework is consistent with how most jurisdictions approach potency thresholds, drawing a line between hemp-derived low-THC products and higher-potency preparations.

Recreational use in public was explicitly addressed by the Thai government too. Even after delisting, the FDA and Ministry of Public Health issued guidance that smoking cannabis in public spaces could be pursued under public nuisance laws, and several Thai municipalities moved to create local prohibitions. The idea that the 2022 change meant fully open recreational use was always a misreading, one spruiked heavily by tourist-facing businesses that moved quickly to open cannabis dispensaries in Bangkok and Chiang Mai.

Medical cannabis: the earlier, more structured framework

Actually, before the 2022 delisting, Thailand had already established a medical cannabis programme. The Narcotics Act Amendment B.E. 2562 (2019) permitted cannabis for medical and research purposes. That amendment created a licensing system administered by the FDA, allowed approved facilities to cultivate, produce and possess cannabis for medical use, and permitted government pharmaceutical organisations to manufacture cannabis-based preparations.

Clinics and hospitals could apply for licences to prescribe cannabis extracts to patients. The formulary included standardised extracts produced by the Government Pharmaceutical Organisation (GPO). Practitioners required specific training and registration to prescribe within the system.

For Australian readers: this is structurally analogous; though not identical, to how Australia's own Therapeutic Goods Administration manages medicinal cannabis access. In Australia, medicinal cannabis products must be either on the Australian Register of Therapeutic Goods (see our ARTG glossary entry) or accessed via the Special Access Scheme or an Authorised Prescriber arrangement. Products containing THC above the prescribed threshold sit under Schedule 8 (Controlled Drug). These are distinct, separate legal frameworks, Thai law does not affect Australian obligations.

Where things stand now: the unresolved gap

Here is my honest read of the current situation. The 2022 delisting created a legal vacuum that Thailand's regulatory system has not yet filled cleanly. Without the Cannabis and Hemp Act in place, operators have been running under provisional frameworks; food law, cosmetics law, the remaining narcotics provisions, with the FDA issuing circulars to plug gaps as they appear. That is not a stable long-term architecture.

In 2023, Thailand's then-Prime Minister Srettha Thavisin signalled intent to re-restrict cannabis to medical and research use only, reflecting concern that the 2022 change had functionally enabled recreational markets without the regulatory guardrails the government originally envisaged. The re-scheduling debate has been ongoing. As of early 2025, the plant remains delisted, but the political direction has been toward tightening rather than further liberalisation.

Honestly, I find this a fascinating case study in what happens when a delisting runs ahead of a new regulatory act. The gap between "no longer a scheduled narcotic" and "fully legal recreational market" is exactly where enforcement ambiguity lives, and Thailand has been sitting in that gap for three years now.

Hemp, fibre and food: the agricultural side

Separate from the medical and recreational debates, Thai law has for some years permitted licensed hemp cultivation for fibre, seed oil, and food use, provided THC content stays within the permitted threshold. The plant's terpene profile and cannabinoid composition can vary considerably across cultivars, hemp varieties are specifically selected and regulated to stay below the potency thresholds that trigger narcotics classification.

The CBD-dominant extract market for food and beverages has grown significantly since 2022. Products marketed around CBD content have proliferated in Bangkok's health food scene, though the legal basis for health claims remains constrained; Thai FDA rules, like most regulators including Australia's TGA, restrict therapeutic representations on consumer cannabis products.

What Australian travellers and researchers need to know

I'll be direct about this. Australian law applies to Australians regardless of what Thai law permits. Carrying cannabis or cannabis-derived extracts back into Australia is an importation offence under the Criminal Code Act 1995 (Cth) and the Customs Act 1901 (Cth). It doesn't matter whether the product was lawfully obtained in Thailand. The TGA regulates what enters Australia, and unapproved cannabis preparations, however legally purchased abroad, are not exempt from Australian border controls. The Poisons Standard (the document formally titled the Standard for the Uniform Scheduling of Medicines and Poisons) governs scheduling in Australia, not a foreign country's FDA notifications.

For researchers and policy analysts following Thailand's framework, the published literature is useful. The UNODC and WHO have both reported on Southeast Asian cannabis policy shifts. Thailand's own FDA publishes ministerial notifications in Thai, though English summaries are available through academic sources.

I was leafing through a 2021 UNODC report on drug policy in Southeast Asia last weekend; I'd taken it on a long ride out through the Majura Valley and sat with it at a café in Watson on the way back, and the observation that stood out was how quickly the regional picture had shifted just in the years between that report and the 2022 delisting. Policy timelines in this space are short.

A note on cannabinoid chemistry across jurisdictions

One thing worth flagging for readers who follow our glossary content: the cannabinoids regulated under Thailand's framework are the same molecules discussed in Australian clinical and research contexts. CBD, THC, and minor cannabinoids like CBG don't change their chemistry depending on which country's law you're standing in. Their interaction with the endocannabinoid system, including binding activity at CB1 and CB2 receptors; is a matter of pharmacology, not jurisdiction. What changes across borders is classification, permitted use, required manufacturing standards, and what constitutes a lawful product. That distinction matters, especially for Australian readers navigating what is and isn't regulated here at home.

Sources

• Drug Situation in South-East Asia 2021, UNODC
• Medicinal Cannabis Hub, TGA (Australian Government)
• Cannabis policy in Thailand: A narrative review; NCBI/PMC
• WHO Expert Committee on Drug Dependence: Critical Review, Cannabis, WHO

, Marcus Hale, Regulatory researcher, TGA & access law